Q-omics provides the consensus-scored PUS7L profile across patient tissues and cancer cell-line models. PUS7L expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PUS7L is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PUS7L protein abundance shows 23,061 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where PUS7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PUS7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PUS7L survival associations across molecular data types. PUS7L RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PUS7L RNA expression–survival associations across cancer types. High PUS7L expression shows unfavorable associations in UVM, LIHC, KICH, LGG and CESC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PUS7L RNA expression.
This table summarizes PUS7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PUS7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PUS7L shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, KIRP, LIHC and COAD. The KIRC box plot shows higher PUS7L RNA expression in tumor versus normal tissue (log2 FC = +0.427, t-test p < 0.001).
This table shows molecular features associated with PUS7L in patient tissues and cancer cell lines. In patient samples, PUS7L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PUS7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
